

# INTRODUCTION TO LLS **T**HERAPY **A**CCCELERATION **P**ROGRAM

December 2019



# BLOOD CANCERS

**Every 3 minutes someone in the US is diagnosed with a blood cancer.**

**More than one third of blood cancer patients do not survive five years after diagnosis.**

**Despite improved outcomes, we need to do more!**



# OUR MISSION

**Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families**



**More than \$1.3 billion  
invested in research**




**Unparalleled patient  
support and education  
services**



**Advocacy to accelerate  
cures and access**




# LLS Research focuses on discovering and developing therapies to positively impact care for blood cancer patients






# Research by Funding Mechanism - FY18





# Therapy Acceleration Program (TAP) PAGE 6

- Strategic initiative established in 2007
- Accelerate high-risk innovative blood cancer therapeutics
- **Meeting LLS Mission is first priority**
- Generating ROI to further fund LLS Mission is secondary






# Therapy Acceleration Program (TAP) Supports Emerging New Therapies

PAGE 7

- **Venture Philanthropy since 2007**
- **\$120M+ investment**
- **60+ projects**
- **16 in current portfolio**
- **3 FDA Approvals**
  - **Vyxeos (AML)**
  - **Yescarta (DLBCL, tFL, PMBCL)**
  - **Elzonris (BPDCN)**















# Development Stages of TAP Portfolio

	Current	Total
<b><i>Development Phase</i></b>		
Phase II Reg / Phase III	2	7
Phase II (Non Registration)	7	12
Phase I	5	25
Preclinical	1	16
Clinical Trial Networks/ Patient Care	1	4
<b>TOTAL</b>	<b>16</b>	<b>64</b>

**Current Focus:**  
**Clinical Proof of Concept**



# Select Projects in Current TAP Portfolio PAGE 9

THERAPY	TARGET/MODALITY	INDICATION(S)	PHASE I	PHASE II	PHASE II REG/ PHASE III
Magrolimab + azacitidine	Anti-CD47 Antibody	MDS			
Cobomarsen	miR-155 Small Molecule	Cutaneous T-cell Lymphoma			
Magrolimab + rituximab	Anti-CD47 Antibody	Lymphoma			
COPIKTRA (duvelisib)	PI3Kδ/γ Small Molecule	Peripheral T-cell Lymphoma			
X4P-001 + ibrutinib	CXCR4 Small Molecule	Waldenstrom Macroglobulinemia			
STRO-001	Anti-CD74 Antibody Drug Conjugate	Lymphoma Myeloma			
SEL120	CDK8/19 Small Molecule	AML			
NEXI-001	Cell Therapy	Post-transplant AML			
JNJ-40346527	CSF-1R Small Molecule	AML			
NK cells + ALT-803	Cell Therapy	Heme Malignancies			

**BEATING CANCER IS IN OUR BLOOD.**






- Open to funding application year round
- All hematological indications
- Focuses on therapeutics development in the clinic
- Typically \$2-6M dollars (co-funding for companies)
  - equity or milestone based
- Applicants fill out 1-page Inquiry Form to start the process

**How to apply for TAP: [www.lls.org/therapy-acceleration-program](http://www.lls.org/therapy-acceleration-program)**



# LLS TAP Funding Is Competitive



Average annual number; typically 3-6 month to reach TAP Committee Review



- **Subcommittee of LLS National Board**
- Members consist of KOLs, IP lawyer, VC-investors in biotech, Industry veterans
- TAP Research performs S&E and recommends TAP projects to the Committee
- Company presents to the TAP Committee
- The Committee may approve, conditionally approve or reject company funding request
- Committee approval provides Research BD to proceed to Term Sheet and then formal Agreement



- **High Unmet Medical Need**
- Innovative Science
- First-in-Class
- High potential to impact clinical practice
- Clinical PoC Study or Registration-Directed Study
- Strong IP Position
- Competent Management Team
- Solid Corporate Finance



# Why Companies Come to TAP in addition to \$\$

- Deep knowledge of blood cancer landscape
- Expertise in hem/onc clinical development within LLS and via KOLs
- Connections to patients
- Advocacy efforts for patients
- Biotech companies leverage LLS approval to raise additional funds
- Track record of success



# TAP is Bridging the Gap for Biotech

PAGE 15



**BEATING CANCER IS IN OUR BLOOD.**

 **LEUKEMIA &  
LYMPHOMA  
SOCIETY®**






# THANK YOU

**We have one goal: A world without blood cancers**





# FY18 Research Spend by Disease



**Research Budget: \$52.6 Million**



# Unmet Medical Need

- An indication with no standard of care
- An indication where standard of care yield unsatisfactory outcomes
- A substantial population of patients relapse from or are refractory to currently available treatment options
- Current standard of care include unfavorable toxicity - Chemo-free or less toxic treatments if efficacy is not compromised
- A more convenient regimen to benefit a large portion of the patients with the disease - Oral vs. IP or IV for indolent disease management